As per the deal, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys.
Anadys president and CEO Steve Worland said Roche’s capabilities and experience in HCV would provide the best chance of success for the new potential treatments to reach hepatitis C patients.
Roche Pharma Research and Early Development global head Jean-Jacques said the company aims to provide a powerful combination of therapies that can cure, even without the use of interferon.
"Anadys’ compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance," Jacques added.